Bristol-Myers Squibb Co. (BMY)

The company now

Bristol Myers Squibb, the Princeton, New Jersey drugmaker behind the blood thinner Eliquis and the cancer medicine Opdivo, reported second-quarter 2026 revenue of $13.0 billion, up 6 percent 1. Newer medicines, which it calls the Growth Portfolio, rose 15 percent to $7.6 billion, while older ones fell 4 percent as generic copies cut into them 1. The company then raised its 2026 revenue goal to about $49.0 billion to $50.0 billion, from $46.0 billion to $47.5 billion 1.

Eliquis led the gain, with sales up 22 percent to $4.48 billion, after the company cut the drug's US list price, which lowered the rebates it pays 211. BioSpace reported that the company pushed back late-stage results for Cobenfy in Alzheimer's psychosis, now due from early 2027, and for milvexian in atrial fibrillation 12.

Third-quarter results were scheduled for 29 October 2026 10. They are the first full quarter since the FDA's accelerated approval of Zenbexus, a new myeloma pill, in August 14. In early August, reports of merger talks with AstraZeneca were followed by a senior source telling Reuters there were no discussions between the companies 13.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.